atural Killer cell in acute myeloid leukemia

Phase 1

Recruiting

• Conditions: acute myeloid leukemia.; Acute myeloblastic leukemia; C92.0

• Registration Number: IRCT20140818018842N35
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 25 July 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Age 18 years old or more
Recipients of allogeneic Stem Cell Transplantation for high-risk Acute Myeloid Leukemia by ELN classification
Recipients of allogeneic Stem Cell Transplantation from matched or mismatched donors.
MRD = 5% after the first Induction or MRD = 0.1% after the second Induction or MRD = 0.01% before transplantation
Normal organ function

Exclusion Criteria

Second allogeneic Stem Cell Transplantation
Active or uncontrolled infection
Acute graft versus host disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of Patients With Grades 3-5 of Natural Killer cell infusion-related Adverse Events. Timepoint: Daily during the first seven days after the injection. Method of measurement: History, Physical exam, and lab test.;Relapse Incidence. Timepoint: one year after infusion. Method of measurement: Bone marrow aspiration and biopsy.